Please login to the form below

Pharma Market Research Report - Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016
2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. Last year the FDA approved 48 drugs in rare diseases, including both novel and repurposed drugs.

Rare diseases are attractive to pharma for a number of reasons. Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced regulatory fees, tax incentives and line extensions. Secondly, although patient populations for each disease in every market are small, if the drug gains approval across a number of indications, the manufacturer can increase its potential revenue. Thirdly, if successful, manufacturers have the opportunity to be a market leader in a niche area.

Find out more:

9th February 2016



Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Chester House
Fulham Green
81-83 Fulham High Street
United Kingdom